Oppenheimer Asset Management Inc. Acquires 32,203 Shares of Pfizer Inc. (NYSE:PFE)

Oppenheimer Asset Management Inc. increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 11.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 323,471 shares of the biopharmaceutical company's stock after purchasing an additional 32,203 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Pfizer were worth $8,197,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Rialto Wealth Management LLC purchased a new position in Pfizer during the fourth quarter worth $26,000. Clarity Asset Management Inc. purchased a new position in Pfizer during the fourth quarter worth $27,000. Gould Capital LLC boosted its stake in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer during the fourth quarter worth $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer during the fourth quarter worth $30,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. UBS Group lifted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Stock Up 0.3%

Shares of PFE opened at $24.04 on Tuesday. The firm has a market capitalization of $136.68 billion, a P/E ratio of 17.42, a P/E/G ratio of 0.87 and a beta of 0.57. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The firm has a fifty day moving average price of $23.30 and a 200-day moving average price of $24.88.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same period in the prior year, the firm earned $0.82 earnings per share. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.15%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.